



## eureKARE opens registration for inaugural SynBio Day

- *Agenda for the event, featuring leaders in synthetic biology, now released*
- *Free virtual event on 10 November 2021; delegates required to register [here](#)*
  - *eureKAWARDS winner will be announced at the event*

**Luxembourg and Paris, France – 8 October 2021:** eureKARE ("the Company"), a pioneering new company focused on financing and building next generation biotechnology companies in the disruptive fields of synthetic biology and the microbiome, announces today that registration has opened for its inaugural **eureKARE SynBio Day**, taking place on November 10<sup>th</sup>, 2021.

The event will feature presentations from prominent leaders in synthetic biology across Europe and the United States speaking on core issues in the field, and include a roundtable discussion, networking, the eureKAWARDS finalists' pitches and announcement of the winner.

The eureKARE SynBio Day will be an opportunity to get to know key opinion leaders in the European and global synthetic biology space. Dr. Iordanis Arzimanoglou, Programme Manager of Health and Biotechnology for the European Innovation Council and SMEs Executive Agency (EISMEA) will open the day, highlighting the synthetic biology-based new economy and associated trends.

Speakers at the event include: Prof. Dr. Petra Schwille (Head of the Department of Cellular and Molecular Biophysics, Max Planck Institute of Biochemistry), Prof. Pamela Silver (Team Leader, Harvard Medical School), Dr. David Bikard (CTO and Co-founder of Eligo Biosciences), Dr. Siyuan Chen (CTO at Twist Bioscience), and Dr. André Choulika (CEO and Board Director of Collectis), who will present trends in their respective topics.

Professor Antoine Danchin, French geneticist and Chairman of eureKARE's Scientific Advisory Board, will give the closing remarks at the end of the day.

Details of the roundtable discussion being held during the event will be published in due course.

### Agenda:

- 09:00: Welcome from Rodolphe Besserve, CEO of eureKARE
- 09:05: Opening Speech from Dr Iordanis Arzimanoglou, EIC Program Manager, Health and Biotechnology
- 09:30: Speaker session featuring Prof. Dr. Petra Schwille and Dr. David Bikard
- 10:30: Roundtable discussion - *Major challenges in synthetic biology, today and tomorrow*
- 12:00: Morning Keynote Speech by Dr. André Choulika
- 12:30-1:30 1:1 Networking Round
- 13:30: Pitch Session – eureKAWARDS finalists
- 15:45: Speaker Session featuring Dr. Pamela Silver and Dr. Siyuan Chen

- 16:45: Coffee break
- 17:00: Closing Keynote by Professor Antoine Danchin
- 17:30: Announcement of the winner of the eureKAWARDS 2021
- 18:00: 1:1 Networking Hour
- 19:00: End of Day

**Serge Pampfer, eureKARE CSO, commented:** *“We await our inaugural SynBio Day with great anticipation and look forward to welcoming industry experts and enthusiasts alike to take part in what will be an exciting and informative event. I’m thrilled to welcome our highly renowned speakers to join us and wish all participants in the eureKAWARDS the best of luck!”*

Registration to attend eureKARE’s SynBio Day virtually, is now open [here](#).

To take part in the first annual eureKAWARDS, please visit [eurekare.eu/eurekawards](http://eurekare.eu/eurekawards) for further information and to submit your application. The application portal will remain open until October 10<sup>th</sup>, 2021.

- End -

### **About eureKARE**

eureKARE is a unique project development company dedicated to investing and developing next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology. eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry.

### **For more information**

#### **eureKARE SA**

Marina Shapochnik, Head Investor Relations

[marina.shapochnik@eurekare.eu](mailto:marina.shapochnik@eurekare.eu)

#### **Consilium Strategic Communications**

Amber Fennell, Sukaina Virji, Genevieve Wilson

+44 (0) 203 709 5000

[eurekare@consilium-comms.co](mailto:eurekare@consilium-comms.co)